Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
VERA 
Vera Therapeutics Inc (VERA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/12/2025: VERA (3-star) is a STRONG-BUY. BUY since 11 days. Simulated Profits (47.56%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
14 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $69.92
1 Year Target Price $69.92
| 9 | Strong Buy |
| 4 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 629.43% | Avg. Invested days 33 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 12/12/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.54B USD | Price to earnings Ratio - | 1Y Target Price 69.92 |
Price to earnings Ratio - | 1Y Target Price 69.92 | ||
Volume (30-day avg) 14 | Beta 1.21 | 52 Weeks Range 18.53 - 50.16 | Updated Date 12/13/2025 |
52 Weeks Range 18.53 - 50.16 | Updated Date 12/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.99 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -38.12% | Return on Equity (TTM) -73.25% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3114974122 | Price to Sales(TTM) - |
Enterprise Value 3114974122 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.6 | Shares Outstanding 70986890 | Shares Floating 44059862 |
Shares Outstanding 70986890 | Shares Floating 44059862 | ||
Percent Insiders 0.88 | Percent Institutions 102.86 |
About Vera Therapeutics Inc
Exchange NASDAQ | Headquaters Brisbane, CA, United States | ||
IPO Launch date 2021-05-14 | Founder, President, CEO & Director Dr. Marshall W. Fordyce M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 224 | Website https://veratx.com |
Full time employees 224 | Website https://veratx.com | ||
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases. The company's lead product candidate consists of atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN). It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.